Inflammatory cardiomyopathy

Article written and reviewed by Dr Luca Moretti

Inflammatory cardiomyopathy is defined by the association of chronic myocarditis, cardiac dysfunction and ventricular remodeling. This formulation distinguishes it both from the simple presence of immune cells in tissue, which must be interpreted using quantitative and morphological criteria, and from chronic myocarditis with still-preserved function. The most recognizable phenotype is the dilated phenotype, but the absence of dilation does not exclude the diagnosis when a non-dilated hypokinetic phenotype with ventricular dysfunction and remodeling is present; an arrhythmogenic substrate may also coexist.

The concept is clinically important because it links two dimensions that do not always proceed in parallel. Inflammatory activity may be reversible and respond to etiologic or immunomodulatory therapy, whereas myocyte loss, fibrosis and neurohormonal remodeling may become autonomous and require ongoing heart failure treatment. An improved ejection fraction does not demonstrate that inflammation has disappeared and, conversely, remission of the infiltrate does not guarantee recovery of a structure that has already been remodeled.

The true prevalence is unknown because endomyocardial biopsy is performed only in a selected proportion of non-ischemic cardiomyopathies and immunohistochemical criteria have not been applied uniformly across registries. Inflammation may be identified in subgroups of patients initially classified as having idiopathic dilated cardiomyopathy, but demonstrating it does not automatically establish causality or justify immune therapy. The observed frequency depends on disease phase, number and location of samples, pathological method, testing for viral genome and center characteristics.

The natural history includes remission with reverse remodeling, stable dysfunction, inflammatory recurrences, progression to advanced heart failure and electrical manifestations disproportionate to pump impairment. Risk is defined by etiology, histologic subtype, biventricular function, amount and location of scar, genotype and response over time. For this reason, inflammatory cardiomyopathy is not a static diagnosis but an integrated formulation that must specify activity, cause, mechanical and electrical phenotype and the proportion of irreversible injury.

Etiology, Pathogenesis and Pathophysiology

A cardiotropic infection may initiate the process through direct replication, cytotoxic injury and activation of innate immunity, but subsequent evolution depends on the ability to eliminate the agent and terminate the response. Enteroviruses and adenoviruses have shown an association with persistence and dysfunction in subgroups, whereas the significance of parvovirus B19 is more complex because its genome may be detected in the endothelium even in people without cardiomyopathy. Agent, load, cellular location and transcriptional activity must therefore be considered together, avoiding the conversion of a positive qualitative PCR into an automatic diagnosis of viral cardiomyopathy.

When the agent is eliminated but the response persists, molecular mimicry, epitope spreading, exposure of cardiac antigens and inadequate regulatory T-cell function may maintain an autoimmune circuit. Cytotoxic T lymphocytes, helper cells, macrophages and autoantibodies interfere with membranes, receptors, mitochondrial metabolism and calcium handling, producing contractile depression that may initially be more functional than necrotic. HLA expression and an increase in immune cells on immunohistochemistry document activation, but their significance must be correlated with morphology and the clinical picture.

Systemic autoimmune diseases, sarcoidosis, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndromes and giant-cell myocarditis cause cardiomyopathy through distinct mechanisms; immune complexes, vasculitis, granulomas, eosinophil degranulation and T-cell cytotoxicity produce different distributions of necrosis and fibrosis and require their own treatments. Extracardiac activity may not reflect myocardial activity, so clinical remission of the systemic disease is not sufficient to exclude a still-active cardiac process.

Drugs and toxins may sustain injury if exposure continues or trigger an immune response that persists after withdrawal. Checkpoint inhibitors, clozapine and hypersensitivity reactions are examples in which the chronology of exposure, extracardiac findings and tissue findings modify the strategy. Alcohol and sympathomimetic substances may act as concurrent causes of dysfunction and make it particularly difficult to separate the inflammatory component from the toxic component; diagnosis should therefore avoid monocausal explanations when multiple mechanisms are plausible.

A genetic predisposition may precede the inflammatory episode and modify its intensity, distribution and consequences. DSP variants are associated with recurrent pain, troponin elevation and subepicardial LGE, whereas TTN, FLNC and other cardiomyopathy genes have been observed more frequently in complicated forms. In this context, mechanical stress promotes cell death and immune signaling, while inflammation accelerates injury in structurally vulnerable tissue; distinguishing cause from amplifier is not always possible, but recognition of a genetic substrate changes counseling, family screening and arrhythmic risk assessment.

Cardiomyocyte loss induces replacement and interstitial collagen deposition, wall thinning, dilation and alteration of the mitral apparatus; increased wall stress activates the sympathetic system, renin-angiotensin, aldosterone and profibrotic pathways, making remodeling progressively independent of the initial event. Fibrosis also fragments conduction and creates reentry corridors, so ventricular tachycardia and sudden death may emerge even after troponin and edema have normalized.

The reversible component includes edema, cytokine-mediated contractile depression, metabolic alteration and immune activation, whereas replacement necrosis, mature scar and genetic structural defects do not regress. The balance between these components explains why some patients recover rapidly with heart failure therapy and causal treatment while others progress despite biological remission. The realistic therapeutic goal is to interrupt active injury and promote reverse remodeling, without confusing functional recovery with complete anatomical restitution.

The microcirculation and endothelium participate in the process through expression of adhesion molecules, increased permeability and impaired vasodilator reserve. This contribution may reduce oxygen delivery even in the absence of epicardial stenoses and amplify dysfunction caused by cytokines and wall stress. Demonstration of microvascular dysfunction does not, however, establish an inflammatory cause on its own, because diabetes, hypertension and other cardiomyopathies produce similar findings; its value emerges from convergence with tissue, imaging and trajectory.

Clinical Manifestations

Onset may follow documented myocarditis or be insidious, with reduced exercise capacity that the patient attributes to deconditioning or an intercurrent illness. Dyspnea, orthopnea, fatigue, weight gain and edema reflect increased filling pressures and reduced output, whereas chest pain and a new rise in troponin suggest a superimposed phase of activity. The temporal sequence must be reconstructed from previous reports and images, because comparison distinguishes persistent dysfunction from a true recurrence.

Electrical manifestations include premature beats, ventricular tachycardias, atrial fibrillation, conduction blocks, presyncope and syncope. An increasing arrhythmic burden may precede mechanical deterioration, and correlation between symptoms and rhythm requires prolonged Holter monitoring or a loop recorder when episodes are infrequent. Sudden syncope without prodromes, sustained tachycardia, appropriate ICD therapies and arrhythmias during exercise define a high-risk phenotype, even if ejection fraction has improved.

On physical examination, the picture ranges from complete compensation to advanced congestion. Jugular venous distension, hepatojugular reflux, hepatomegaly, ascites and edema indicate increased right-sided pressures, whereas crackles, a third heart sound and functional mitral regurgitation more often accompany left-sided impairment. Low blood pressure, cold extremities, reduced pulse pressure, oliguria and sarcopenia indicate an advanced stage in which evaluation for replacement therapies should not be delayed.

Rash, arthritis, Raynaud phenomenon, asthma, neuropathy, eosinophilia, uveitis, lymphadenopathy, ptosis and muscle weakness may reveal a systemic cause and provide a safer extracardiac site for biopsy. The absence of these manifestations does not exclude a form confined to the heart. Drugs, immunotherapies, supplements, substances of abuse and travel must also be recorded with precise dates, because a coherent temporal relationship may guide tissue analysis and withdrawal of exposure.

Family history should cover at least three generations and investigate cardiomyopathy, sudden death, transplantation, pacemaker or defibrillator implantation at a young age and episodes labeled as myocarditis. Familial recurrence, ring-like or subepicardial LGE patterns and hot phases increase suspicion of a genetic basis. A variant must nevertheless be classified according to shared standards, because a variant of uncertain significance does not prove causality and cannot by itself determine device implantation or invasive screening.

In children, the disease may present with poor growth, feeding difficulty, tachypnea and reduced activity, whereas adolescents and young adults more often show pain, arrhythmias and recurrences. Pregnancy, infections and treatment withdrawal may unmask reduced reserve in previously compensated individuals. Discordance among symptoms, biomarkers and function is common and makes it necessary to follow the clinical trajectory rather than assigning absolute meaning to a single assessment.

Exercise limitation does not depend only on ejection fraction. Chronotropic incompetence, dynamic mitral regurgitation, increased pulmonary pressures, right ventricular dysfunction, deconditioning and reduced peripheral oxygen extraction may produce substantial symptoms even after apparent systolic recovery. Defining the predominant mechanism prevents every episode of dyspnea from being attributed to residual inflammation and guides rehabilitation, hemodynamic therapy and the search for concurrent respiratory, hematologic or metabolic causes.

Investigations and Diagnosis

First-line evaluation includes ECG, troponin, natriuretic peptide, complete blood count with differential, CRP, renal, hepatic and thyroid function and electrolytes; normal biomarkers do not exclude low-grade activity, whereas elevated values require comparison with baseline and alternative causes. Eosinophils, CK, autoimmune testing, blood cultures and infectious investigations are requested according to the phenotype, avoiding non-selective panels that increase incidental results without clarifying the cardiac mechanism.

Echocardiography measures volumes, geometry, biventricular function, strain, regurgitation, pressures, effusion and thrombi. Progressive dilation, reduced strain and functional mitral regurgitation document remodeling, but function may remain preserved in focal and predominantly arrhythmic disease. Serial comparison with a consistent technique is more informative than isolated differences close to measurement variability.

CMR characterizes edema, native T1, extracellular volume and LGE, separating recent activity from mature scar, with increasing limitations in chronic forms. Subepicardial or intramural LGE documents a non-ischemic distribution, while septal location, extent and persistence contribute to prognosis. CMR does not, however, identify the type of infiltrate, the presence of viral genome or sensitivity to a specific immunotherapy and is therefore insufficient when this information changes care.

Diagnosis requires chronic myocarditis associated with cardiac dysfunction and ventricular remodeling and does not have a single self-sufficient clinical criterion. Endomyocardial biopsy remains the reference for histology, immunohistochemistry and molecular testing when etiologic therapy is being considered, disease progresses despite treatment, arrhythmias or blocks develop, or granulomatous, eosinophilic or giant-cell forms are suspected. Multiple samples, correct preservation and an experienced laboratory are prerequisites for diagnostic validity.

The Dallas criteria identify an inflammatory infiltrate with non-ischemic myocyte necrosis or degeneration, but are limited by sampling error and interpretive variability. Immunohistochemistry increases sensitivity, quantifies cells and subpopulations and documents HLA expression; thresholds must be applied with validated methods and integrated with morphology and clinical findings. Viral genome testing must distinguish agents, load and activity, because simple qualitative positivity, especially for low-load B19V, is insufficient to define active viral cardiomyopathy.

18F-FDG PET and extracardiac imaging are particularly useful in sarcoidosis and focal inflammation, provided that preparation suppresses physiological myocardial uptake. Biopsy of a lymph node, lung, skin or muscle may provide a systemic diagnosis at lower risk, although it does not replace cardiac tissue when the question concerns a specific myocardial infiltrate. Coronary disease, valve disease, rhythm, blood pressure, toxins and endocrinopathies must be reassessed because an old diagnosis of myocarditis does not exclude new common causes of dysfunction.

Holter monitoring, exercise testing and, at times, a loop recorder quantify electrical risk, whereas cardiopulmonary exercise testing measures oxygen consumption, VE/VCO2 slope and reserve. Right heart catheterization is reserved for advanced heart failure or discrepancies in which output and pressures alter therapeutic choice. Genetic testing is indicated especially in familial, recurrent, complicated or arrhythmic phenotypes and completes a diagnosis that must specify activity, etiology, function and genotype.

Right heart catheterization is not necessary in every stable patient, but becomes valuable when congestion and perfusion are difficult to define, pulmonary pressure influences advanced decisions or the response to therapy is discordant with echocardiography. Filling pressures, output and resistance clarify the hemodynamic profile without distinguishing inflammatory etiology; in compensated patients, cardiopulmonary exercise testing quantifies functional capacity and prognosis and separates circulatory limitation from deconditioning or pulmonary disease.

Treatment and Prognosis

Guideline-directed heart failure therapy is the foundation of management. An ARNI or an ACE inhibitor or ARB, a beta-blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor are introduced and titrated according to ejection fraction, blood pressure, renal function and potassium, while diuretics control congestion. Treatment is often continued after recovery, especially when scar, a high-risk genotype or an unremoved cause persists, because normalization of function does not mean disappearance of the substrate.

Immunosuppression is indicated in specific immune-mediated subtypes and may be considered in biopsy-documented, virus-negative lymphocytic inflammatory cardiomyopathy. In the TIMIC trial, patients with chronic dysfunction unresponsive to conventional therapy and biopsy-proven inflammation without detectable viral genome received prednisone and azathioprine or placebo, with functional improvement in the treated group that was subsequently confirmed during follow-up extending to twenty years. These findings support a biopsy-guided strategy, but cannot be extended to unsampled cardiomyopathies or those with clinically relevant viral genome.

The historical Myocarditis Treatment Trial did not demonstrate benefit from immunosuppression applied without modern virologic and immunohistochemical characterization, highlighting the limitation of a uniform approach. Giant-cell myocarditis, sarcoidosis, eosinophilic myocarditis and checkpoint inhibitor toxicity require different regimens and dedicated monitoring. Before and during treatment, infectious screening, vaccination, prophylaxis and monitoring of cytopenias, metabolism, bone, kidney and liver are planned because treatment-related risk increases with intensity and duration.

Antimicrobial therapy is reserved for proven or strongly suspected agents for which effective treatment exists. Studies of interferon beta in persistent enterovirus- or adenovirus-associated cardiomyopathies have suggested viral clearance and improvement in selected settings, but do not constitute a generalizable empiric strategy. For many viruses no treatment capable of eradicating the myocardial reservoir is available, and molecular findings should be discussed with expert laboratories and centers before immunosuppression is modified.

Atrial fibrillation, ventricular tachycardias and conduction disorders are treated according to guidelines while concurrently addressing inflammatory activity when present. Ablation is more effective on a mature scar than during unstable inflammation, whereas indications for ICD and CRT integrate function, arrhythmias, genotype, LGE and duration of optimal therapy. A wearable cardioverter-defibrillator may provide temporary protection in selected patients during recovery and risk redefinition.

Follow-up coordinates symptoms, NYHA class, volume status, troponin, natriuretic peptide, echocardiography, CMR or PET and rhythm monitoring; response includes remission of inflammation, reverse remodeling and electrical stabilization, not merely an increase in ejection fraction. Physical activity and rehabilitation are tailored to function and arrhythmic risk, avoiding intense exercise during an active phase but also avoiding permanent inactivity based solely on stable LGE.

Extensive or septal LGE, right ventricular dysfunction, sustained arrhythmias, advanced NYHA class, high-risk genotype and lack of response identify a less favorable prognosis. When repeated hospitalizations, hypotension, organ failure or progressive intolerance to therapies develop, evaluation for ventricular assist device and transplantation should precede irreversible deterioration. Prognosis improves when etiologic characterization and heart failure therapy proceed together, rather than waiting for one to replace the other.

Improvement in ejection fraction does not justify automatic withdrawal of neurohormonal therapy because the substrate may only be in remission and remodeling may recur. The decision considers whether the cause has been removed or persists, genotype, fibrosis, ventricular dimensions and tolerability, with closer monitoring if dose reduction is considered necessary. In recurrent congestion, education regarding weight, symptoms and adherence helps recognize deterioration before hospitalization becomes necessary.

Complications

Progression to chronic heart failure results from the combination of myocyte loss, fibrosis, dilation and neurohormonal activation. Functional mitral regurgitation increases volume overload and accelerates remodeling, while right-sided involvement produces venous congestion, liver disease and worsening renal function. Repeated hospitalizations, cachexia and frailty reduce treatment tolerance and may compromise candidacy for advanced options.

Intramural or subepicardial scar creates slow conduction and reentry, with premature beats, ventricular tachycardia and a risk of sudden death that may persist after recovery of ejection fraction. New arrhythmias may reflect either substrate maturation or inflammatory reactivation; troponin, imaging and clinical course help distinguish the two mechanisms, which require electrical protection and treatment of activity, respectively.

Atrioventricular block and sinus node dysfunction result from fibrosis or infiltration of the conduction system and are particularly relevant in sarcoidosis, giant-cell myocarditis and immune-mediated forms. A new block in a disease that has already been diagnosed should prompt investigation for reactivation and reconsideration of the most appropriate device, because a simple pacemaker does not protect against ventricular risk when the substrate is arrhythmogenic.

Stasis, dilation, akinesia and atrial fibrillation promote intracardiac thrombi and cerebral or peripheral embolism. Contrast echocardiography and CMR increase sensitivity when the apex is difficult to visualize, whereas anticoagulation follows demonstration of thrombus or standard indications. Inflammation itself is not a universal indication, and bleeding risk must be considered especially when biopsies or procedures are planned.

Recurrences add edema, necrosis and new fibrosis to an already vulnerable heart and may be triggered by re-exposure, autoimmune disease, persistent infection or a genetic hot phase. Recurrence changes the indication for biopsy and genetic testing and requires a new etiologic assessment, not automatic repetition of the previous treatment. A diagnosis initially defined as idiopathic should be reopened when a second episode occurs.

Immunosuppression may cause opportunistic infections, viral reactivations, cytopenias, malignancies, osteoporosis, diabetes and organ toxicity. Incorrectly treating biologically active viral persistence may hinder clearance, whereas withholding immune therapy from a virus-negative autoimmune form allows reversible injury to progress. The quality of the biopsy and laboratory therefore constitutes a concrete component of therapeutic safety.

End-stage disease may require ventricular assist device or transplantation and may be complicated by pulmonary hypertension, right heart failure, infection and renal or hepatic injury. Systemic activity and the risk of recurrence in the graft must be assessed before transplantation; early referral preserves options that may be lost when heart failure is considered pharmacologically treatable beyond the point of reversibility.

Right ventricular dysfunction and secondary pulmonary hypertension represent an important prognostic transition because they limit output, renal function and drug tolerance; chronic elevation of left-sided pressures may evolve into a less reversible vascular component, complicating ventricular assistance and transplantation. Recognizing it while it is still predominantly post-capillary allows optimization of volume status, mitral regurgitation and left ventricular function before pulmonary vascular remodeling narrows therapeutic options.